EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Low Surgery Rates in Early Crohn’s Disease: Results from a Prospective Population-Based Inception Cohort—The Inflammatory Bowel Disease in South-Eastern Norway III Study

Charlotte Lund iD, Vibeke Strande iD, Milada Hagen iD, May-Bente Bengtson iD, Raziye Boyar, Trond Espen Detlie iD, Svein Oskar Frigstad iD, Asle W Medhus iD, Magne Henriksen iD, Kristina I Aass Holten iD, Øistein Hovde iD, Gert Huppertz-Hauss iD und 14 weitere

Inflammatory Bowel Diseases · 01.08.2025 · 31 (8) · 2173-2183

DOI: 10.1093/ibd/izae297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 19.12.2024. Verfasst von Charlotte Lund und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Oslo University Hospital, PO Box 4956 Nydalen, 0424 Oslo, Norway. Hauptthemen laut MEDLINE: Crohn Disease, Digestive System Surgical Procedures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer, Tillotts Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The emergence of biologic therapy has coincided with a decline in surgery rates for Crohn’s disease (CD). This study aims to describe the disease course, including intra-abdominal surgery rates, biologic therapy use, and variables associated with biologic therapy initiation in a cohort of newly diagnosed CD patients.

Methods

The Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) III study is a population-based inception cohort study. From 2017 to 2019, newly diagnosed inflammatory bowel disease patients were included for prospective follow-up. The present study included CD patients ≥ 18 years. Clinical, endoscopic, and demographic data were collected at diagnosis and 1-year follow-up. Data were analyzed by using the Kaplan–Meier method and regression analyses.

Results

In total, 424 CD patients (median age 37.0 years (range 18-80), female 55.0%) were included. At diagnosis, 50.5% presented with ileal disease and 80.7% with inflammatory behavior. Within a 1-year follow-up, 39.6% of patients received their first biologic therapy and 5.2% required intra-abdominal surgery. Systemic steroid treatment, CRP ≥ 5.0 mg dL−1, Harvey–Bradshaw Index score > 4, ileocolonic disease and penetrating disease behavior at diagnosis were independently associated with increased risk of initiation of biologic therapy, while age > 40 years was associated with decreased risk.

Conclusion

A high proportion of patients had ileal disease and inflammatory behavior at diagnosis. Still, nearly 40% started biologic therapy within the 1-year follow-up, while only 5% required intra-abdominal surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseDigestive System Surgical ProceduresHumansFemaleMaleAdultNorwayProspective StudiesMiddle AgedYoung AdultAdolescentAgedFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

Crohn’s diseaseIBDbiologic therapyepidemiologyintra-abdominal surgery

Autor:innen und Institutionen

  • Department of Gastroenterology, Oslo University Hospital, PO Box 4956 Nydalen, 0424 Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway.
  • Department of Medicine, Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, PO Box 4970 Nydalen, 0440 Oslo, Norway.
  • Department of Gastroenterology, Lovisenberg Diaconal Hospital, PO Box 4970 Nydalen, 0440 Oslo, Norway.
  • Department of Public Health, Oslo Metropolitan University, PO Box 4 St. Olavs plass, 0130 Oslo, Norway.
  • Department of Gastroenterology, Tønsberg Hospital, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway.

ORCID-Profile: Charlotte Lund, Vibeke Strande, Milada Hagen, May-Bente Bengtson, Trond Espen Detlie, Svein Oskar Frigstad, Asle W Medhus, Magne Henriksen, Kristina I Aass Holten, Øistein Hovde, Gert Huppertz-Hauss, Ingunn Johansen, Randi Opheim, Gøri Perminow, Petr Ricanek, Roald Torp, Carl Magnus Ystrøm, Ole Høie, Simen Vatn, Vendel A Kristensen, Marte Lie Høivik

Förderung

  • Pfizer
  • Tillotts Pharma

Zitieren

APA

Lund, C., Strande, V., Hagen, M., Bengtson, M. B., Boyar, R., Detlie, T. E., Frigstad, S. O., Medhus, A. W., Henriksen, M., Holten, K. I. A., Hovde, Ø., Huppertz-Hauss, G., Johansen, I., Olsen, B. C., Opheim, R., Pallenschat, J., Perminow, G., Ricanek, P., Torp, R., …, & Høivik, M. L. (2025). Low Surgery Rates in Early Crohn’s Disease: Results from a Prospective Population-Based Inception Cohort—The Inflammatory Bowel Disease in South-Eastern Norway III Study. Inflammatory Bowel Diseases, 31(8), 2173-2183. https://doi.org/10.1093/ibd/izae297

Vancouver

Lund C, Strande V, Hagen M, Bengtson MB, Boyar R, Detlie TE, et al. Low Surgery Rates in Early Crohn’s Disease: Results from a Prospective Population-Based Inception Cohort—The Inflammatory Bowel Disease in South-Eastern Norway III Study. Inflammatory Bowel Diseases. 2025;31(8):2173-2183. doi:10.1093/ibd/izae297

BibTeX
@article{Lund2025,
  author = {Lund, Charlotte and Strande, Vibeke and Hagen, Milada and Bengtson, May-Bente and Boyar, Raziye and Detlie, Trond Espen and Frigstad, Svein Oskar and Medhus, Asle W and Henriksen, Magne and Holten, Kristina I Aass and Hovde, Øistein and Huppertz-Hauss, Gert and Johansen, Ingunn and Olsen, Bjørn Christian and Opheim, Randi and Pallenschat, Jens and Perminow, Gøri and Ricanek, Petr and Torp, Roald and Ystrøm, Carl Magnus and Høie, Ole and Asak, Øivind and Vatn, Simen and Aabrekk, Tone Bergene and Kristensen, Vendel A and Høivik, Marte Lie},
  title = {Low Surgery Rates in Early Crohn’s Disease: Results from a Prospective Population-Based Inception Cohort—The Inflammatory Bowel Disease in South-Eastern Norway III Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {8},
  pages = {2173--2183},
  doi = {10.1093/ibd/izae297}
}
Kostenlos starten →